scholarly article | Q13442814 |
P819 | ADS bibcode | 2013PLoSO...863893D |
P356 | DOI | 10.1371/JOURNAL.PONE.0063893 |
P932 | PMC publication ID | 3655059 |
P698 | PubMed publication ID | 23691109 |
P5875 | ResearchGate publication ID | 236925283 |
P50 | author | Barbara Renga | Q114572165 |
Sabrina Cipriani | Q114572169 | ||
P2093 | author name string | Andrea Mencarelli | |
Stefano Fiorucci | |||
Eleonora Distrutti | |||
P2860 | cites work | NCBI GEO: archive for functional genomics data sets--10 years on | Q24610731 |
Functional bowel disorders and functional abdominal pain | Q24675171 | ||
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation | Q27327276 | ||
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository | Q27860523 | ||
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects | Q33290848 | ||
A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating | Q33434046 | ||
Dose-dependent immunomodulation of human dendritic cells by the probiotic Lactobacillus rhamnosus Lcr35. | Q33886503 | ||
Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. | Q33987389 | ||
Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors | Q34231605 | ||
VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation | Q34428997 | ||
Maternal deprivation affects the neuromuscular protein profile of the rat colon in response to an acute stressor later in life | Q57567017 | ||
VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity | Q60695409 | ||
A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development | Q73130772 | ||
Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission | Q80270928 | ||
Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli | Q83264605 | ||
Effects of Bifidobacterium breve on inflammatory gene expression in neonatal and weaning rat intestine | Q83363194 | ||
Probiotics in man and animals | Q34505006 | ||
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats. | Q35596401 | ||
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver | Q36532353 | ||
The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome | Q36998938 | ||
Is irritable bowel syndrome an inflammatory disorder? | Q37216854 | ||
Development of nociceptin receptor (NOP) agonists and antagonists | Q37680813 | ||
Recently patented and promising ORL-1 ligands: where have we been and where are we going? | Q37697788 | ||
Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists | Q37883405 | ||
Pharmacotherapy for acute pouchitis | Q37903194 | ||
Visceral pain: a review of experimental studies | Q37939840 | ||
VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study | Q39286213 | ||
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome | Q39396709 | ||
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain | Q39694347 | ||
Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients | Q39980879 | ||
Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun | Q40100857 | ||
Basic and clinical aspects of visceral hyperalgesia | Q40666271 | ||
The effects of early rearing environment on the development of GABAA and central benzodiazepine receptor levels and novelty-induced fearfulness in the rat. | Q42620039 | ||
Neonatal maternal separation in the rat impacts on the stress responsivity of central corticotropin-releasing factor receptors in adulthood | Q42661715 | ||
The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. | Q42662550 | ||
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression | Q42942477 | ||
Rectal function and bowel habit in irritable bowel syndrome | Q43307195 | ||
Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. | Q43350989 | ||
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors | Q44333170 | ||
A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. | Q46024960 | ||
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels | Q46726610 | ||
Neonatal maternal separation causes colonic dysfunction in rat pups including impaired host resistance | Q46834985 | ||
Maternal separation alters serotonergic transporter densities and serotonergic 1A receptors in rat brain | Q46986227 | ||
Neonatal maternal separation enhances central sensitivity to noxious colorectal distention in rat. | Q48202749 | ||
Both long and brief maternal separation produces persistent changes in tissue levels of brain monoamines in middle-aged female rats | Q48310651 | ||
Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. | Q48367744 | ||
Maternal separation in neonatal rats elicits activation of the hypothalamic-pituitary-adrenocortical axis: a putative role for corticotropin-releasing factor | Q48379128 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P4510 | describes a project that uses | Cytoscape | Q3699942 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | irritable bowel syndrome | Q838966 |
probiotics | Q1816730 | ||
murine model | Q122890741 | ||
P304 | page(s) | e63893 | |
P577 | publication date | 2013-05-15 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome | |
P478 | volume | 8 |
Q36179096 | Administration of a Multi-Strain Probiotic Product to Women in the Perinatal Period Differentially Affects the Breast Milk Cytokine Profile and May Have Beneficial Effects on Neonatal Gastrointestinal Functional Symptoms. A Randomized Clinical Trial |
Q35534031 | Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction |
Q38376282 | Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges |
Q35532177 | Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. |
Q35111263 | Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model? |
Q36875133 | Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice |
Q37564174 | Chronic Early-life Stress in Rat Pups Alters Basal Corticosterone, Intestinal Permeability, and Fecal Microbiota at Weaning: Influence of Sex. |
Q100491009 | Disruption of Firmicutes and Actinobacteria abundance in tomato rhizosphere causes the incidence of bacterial wilt disease |
Q64257546 | Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties |
Q55612911 | Dynamic changes in morphology, gene expression and microbiome in the jejunum of compensatory-growth rats induced by protein restriction. |
Q35586987 | Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. |
Q36816915 | Gut Microbiome: What We Do and Don't Know |
Q28081092 | Gut Microbiota: A Modulator of Brain Plasticity and Cognitive Function in Ageing |
Q26768550 | Gut microbiota role in irritable bowel syndrome: New therapeutic strategies |
Q55190074 | Heat shock protein 70 protects mouse against post-infection irritable bowel syndrome via up-regulating intestinal γδ T cell's Th17 response. |
Q42268439 | Host-probiotic interaction: new insight into the role of the endocannabinoid system by in vivo and ex vivo approaches |
Q48291685 | Immune response of patients with recurrent aphthous stomatitis challenged with a symbiotic |
Q36191384 | Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice |
Q93097689 | Maternal separation in rodents: a journey from gut to brain and nutritional perspectives |
Q41159790 | Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity. |
Q42098016 | Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels. |
Q90269186 | Microbiota: a novel regulator of pain |
Q34499067 | Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics |
Q34155897 | Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP |
Q48313903 | Oral probiotic treatment of Lactobacillus rhamnosus Lcr35® prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. |
Q94527883 | Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases |
Q27322790 | Spatial Localization and Binding of the Probiotic Lactobacillus farciminis to the Rat Intestinal Mucosa: Influence of Chronic Stress |
Q35867820 | Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome |
Q35087100 | Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities |
Q90705702 | Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome |
Q46438777 | The Role of the Gastrointestinal Microbiota in Visceral Pain |
Q30415125 | The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems |
Q34129427 | The microbiota-gut-brain axis in functional gastrointestinal disorders |
Q35155407 | The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? |
Q35931334 | The potential influence of the microbiota and probiotics on women during long spaceflights |
Q26739291 | The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments |
Q36140404 | VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial |
Q57476129 | Visceral pain: gut microbiota, a new hope? |
Search more.